Genmab | GEN - Assets



Genmab reported DKK6.46B in Assets for its fiscal quarter ending in June of 2025.


Assets Change Date
Agios Pharmaceuticals USD 1.47B 84.28M Jun/2025
Almirall EUR 2.31B 88.18M Jun/2025
Amarin USD 655.68M 29.67M Mar/2025
Amgen USD 87.9B 1.47B Jun/2025
argenx SE 7.18B 973.07M Jun/2025
AstraZeneca USD 112.42B 6.17B Jun/2025
Bayer EUR 105.24B 3.95B Jun/2025
BioMarin Pharmaceutical USD 7.46B 309.33M Jun/2025
Demant DKK 32.64B 190M Jun/2025
Exelixis USD 2.68B 159.17M Jul/2025
Fresenius Medical Care EUR 31.29B 1.44B Jun/2025
Galapagos EUR 3.82B 203.72M Jun/2025
Genmab DKK 6.46B 122M Jun/2025
GlaxoSmithKline GBP 59.26B 1.45B Jun/2025
GN Store Nord DKK 29.49B 451M Jun/2025
GRIFOLS EUR 19.77B 1.21B Jun/2025
Hikma Pharmaceutical USD 5.13B 286M Dec/2024
Insmed USD 2.48B 677.12M Jun/2025
Lonza CHF 19.73B 1.85B Dec/2024
Merck EUR 47.35B 2.02B Jun/2025
Novartis USD 104.4B 4.45B Jun/2025
Regeneron Pharmaceuticals USD 38.22B 674M Jun/2025
Roche Holding CHF 101.8B 6.02B Dec/2024
Sanofi 124.96B 6.93B Jun/2025
UCB EUR 17.35B 1.72B Dec/2024